348 related articles for article (PubMed ID: 26748223)
1. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis.
Verschuren EC; van den Eertwegh AJ; Wonders J; Slangen RM; van Delft F; van Bodegraven A; Neefjes-Borst A; de Boer NK
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):836-842. PubMed ID: 26748223
[TBL] [Abstract][Full Text] [Related]
2. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.
Wang Y; Abu-Sbeih H; Mao E; Ali N; Qiao W; Trinh VA; Zobniw C; Johnson DH; Samdani R; Lum P; Shuttlesworth G; Blechacz B; Bresalier R; Miller E; Thirumurthi S; Richards D; Raju G; Stroehlein J; Diab A
Inflamm Bowel Dis; 2018 Jul; 24(8):1695-1705. PubMed ID: 29718308
[TBL] [Abstract][Full Text] [Related]
3. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab-induced colitis in patients with metastatic melanoma.
De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
[TBL] [Abstract][Full Text] [Related]
5. Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis.
Herlihy JD; Beasley S; Simmelink A; Maddukuri V; Amin A; Kamionek M; Jacobs C; Bossi K; Scobey M
South Med J; 2019 Mar; 112(3):154-158. PubMed ID: 30830228
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab-induced perforating colitis.
Mitchell KA; Kluger H; Sznol M; Hartman DJ
J Clin Gastroenterol; 2013 Oct; 47(9):781-5. PubMed ID: 23632354
[TBL] [Abstract][Full Text] [Related]
7. Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.
Bamias G; Delladetsima I; Perdiki M; Siakavellas SI; Goukos D; Papatheodoridis GV; Daikos GL; Gogas H
Cancer Invest; 2017 Aug; 35(7):443-455. PubMed ID: 28548891
[TBL] [Abstract][Full Text] [Related]
8. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
Minor DR; Chin K; Kashani-Sabet M
Cancer Biother Radiopharm; 2009 Jun; 24(3):321-5. PubMed ID: 19538054
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab-induced acute severe colitis treated by infliximab.
Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and significance of inflammatory bowel disease-like morphologic features in collagenous and lymphocytic colitis.
Ayata G; Ithamukkala S; Sapp H; Shaz BH; Brien TP; Wang HH; Antonioli DA; Farraye FA; Odze RD
Am J Surg Pathol; 2002 Nov; 26(11):1414-23. PubMed ID: 12409717
[TBL] [Abstract][Full Text] [Related]
11. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient.
Merrill SP; Reynolds P; Kalra A; Biehl J; Vandivier RW; Mueller SW
Ann Pharmacother; 2014 Jun; 48(6):806-10. PubMed ID: 24651165
[TBL] [Abstract][Full Text] [Related]
12. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
[No Abstract] [Full Text] [Related]
13. Infliximab for ipilimumab-induced colitis: A series of 13 patients.
Hillock NT; Heard S; Kichenadasse G; Hill CL; Andrews J
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e284-e290. PubMed ID: 27981760
[TBL] [Abstract][Full Text] [Related]
14. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
[TBL] [Abstract][Full Text] [Related]
16. Systematic review: colitis associated with anti-CTLA-4 therapy.
Gupta A; De Felice KM; Loftus EV; Khanna S
Aliment Pharmacol Ther; 2015 Aug; 42(4):406-17. PubMed ID: 26079306
[TBL] [Abstract][Full Text] [Related]
17. Toxic Injury to the Gastrointestinal Tract After Ipilimumab Therapy for Advanced Melanoma.
Shepard B; Trower C; Hendrickson S
J Am Osteopath Assoc; 2018 Jan; 118(1):40-44. PubMed ID: 29309091
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab-induced toxicities and the gastroenterologist.
Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
[TBL] [Abstract][Full Text] [Related]
19. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells.
Lord JD; Hackman RC; Moklebust A; Thompson JA; Higano CS; Chielens D; Steinbach G; McDonald GB
Dig Dis Sci; 2010 May; 55(5):1396-405. PubMed ID: 19507029
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab.
Nahar KJ; Rawson RV; Ahmed T; Tattersall S; Sandanayake N; Kiely CJ; Lo S; Carlino M; Palendira U; Scolyer RA; Long GV; Menzies AM
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]